YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
100 hedge funds and large institutions have $303M invested in Y-mAbs Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2.75% less ownership
Funds ownership: 56.64% → 53.89% (-2.8%)
8% less capital invested
Capital invested by funds: $330M → $303M (-$26.8M)
Holders
100
Holding in Top 10
2
Calls
$1.78M
Puts
–
Top Buyers
| 1 | +$4.92M | |
| 2 | +$2.91M | |
| 3 | +$1.5M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.29M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.23M |
Top Sellers
| 1 | -$11M | |
| 2 | -$9.81M | |
| 3 | -$6.97M | |
| 4 |
Morgan Stanley
New York
|
-$1.97M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.63M |